To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT02683928. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adults With Moderate-to-Severe Atopic Dermatitis
Study identification
- NCT ID
- NCT02683928
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Ichnos Sciences SA
- Industry
- Enrollment
- 64 participants
Conditions and interventions
Conditions
Interventions
- GBR 830 Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2016
- Primary completion
- May 31, 2017
- Completion
- May 31, 2017
- Last update posted
- May 17, 2020
2016 – 2017
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Glenmark Investigational Site 14 | Rogers | Arkansas | 72759 | — |
| Glenmark Investigational Site 5 | Los Angeles | California | 90045 | — |
| Glenmark Investigational Site 3 | San Diego | California | 92123 | — |
| Glenmark Investigational Site 15 | Tampa | Florida | 33624 | — |
| Glenmark Investigational Site 11 | St Louis | Missouri | 63117 | — |
| Glenmark Investigational Site 16 | Berlin | New Jersey | 08009 | — |
| Glenmark Investigational Site 1 | New York | New York | 10029 | — |
| Glenmark Investigational Site 9 | Raleigh | North Carolina | 27612 | — |
| Glenmark Investigational Site 13 | Fairborn | Ohio | 45324 | — |
| Glenmark Investigational Site 2 | Dallas | Texas | 75230 | — |
| Glenmark Investigational Site 17 | Katy | Texas | 77494 | — |
| Glenmark Investigational Site 12 | Webster | Texas | 77598 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02683928, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 17, 2020 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02683928 live on ClinicalTrials.gov.